Agios Pharmaceuticals, Inc.
General ticker "AGIO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.1B (TTM average)
Agios Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 16.1%.
Estimated limits based on current volatility of 1.8%: low 27.36$, high 28.38$
Factors to consider:
- Total employees count: 488 as of 2024
- Top business risk factors: Product development delays, Regulatory and compliance, Public health crises, Operational and conduct risks, Labor/talent shortage/retention
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [18.63$, 37.73$]
- 2026-12-31 to 2027-12-31 estimated range: [17.77$, 35.85$]
Financial Metrics affecting the AGIO estimates:
- Negative: with PPE of -3.7 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -24.46 <= 0.01
- Positive: Shareholder equity ratio, % of 91.97 > 64.29
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Investing cash flow per share per price, % of 24.73 > -0.63
- Positive: Inventory ratio change, % of -5.21 <= -0.75
Short-term AGIO quotes
Long-term AGIO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $26.82MM | $36.50MM | $54.03MM |
| Operating Expenses | $418.31MM | $462.24MM | $526.16MM |
| Operating Income | $-391.49MM | $-425.74MM | $-472.13MM |
| Non-Operating Income | $39.40MM | $1,143.71MM | $58.34MM |
| R&D Expense | $295.53MM | $301.29MM | $339.54MM |
| Income(Loss) | $-352.09MM | $717.97MM | $-413.80MM |
| Taxes | $0.00MM | $44.24MM | $-1.02MM |
| Profit(Loss)* | $-352.09MM | $673.73MM | $-412.78MM |
| Stockholders Equity | $811.02MM | $1,540.96MM | $1,193.11MM |
| Inventory | $19.08MM | $27.62MM | $32.92MM |
| Assets | $937.12MM | $1,663.20MM | $1,297.22MM |
| Operating Cash Flow | $-296.06MM | $-389.84MM | $-372.98MM |
| Capital expenditure | $1.00MM | $1.69MM | $4.32MM |
| Investing Cash Flow | $239.57MM | $363.44MM | $377.18MM |
| Financing Cash Flow | $5.43MM | $14.44MM | $8.68MM |
| Earnings Per Share** | $-6.33 | $11.86 | $-7.12 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.